Show simple item record

dc.contributor.authorMolinet Dronda, Francisco
dc.contributor.authorBlesa, Javier
dc.contributor.authorLopez-Gonzalez del Rey, Natalia
dc.contributor.authorJuri, Carlos
dc.contributor.authorCollantes, María
dc.contributor.authorPineda-Pardo, José A.
dc.contributor.authorTrigo-Damas, Inés
dc.contributor.authorIglesias, Elena
dc.contributor.authorHernández, Ledia F.
dc.contributor.authorRodríguez-Rojas, Rafael
dc.contributor.authorGago, Belén
dc.contributor.authorEcay, Margarita
dc.contributor.authorPrieto, Elena
dc.contributor.authorGarcía-Cabezas, Miguel Ángel
dc.contributor.authorCavada, Carmen
dc.contributor.authorRodríguez-Oroz, Mari Cruz
dc.contributor.authorPeñuelas, Iván
dc.contributor.authorObeso, José
dc.date.accessioned2025-01-20T17:55:31Z
dc.date.available2025-01-20T17:55:31Z
dc.date.issued2022
dc.identifier.citationMolinet-Dronda, F., Blesa, J., Del Rey, N. L. G., Juri, C., Collantes, M., Pineda-Pardo, J. A., ... & Obeso, J. A. (2022). Cerebral metabolic pattern associated with progressive parkinsonism in non-human primates reveals early cortical hypometabolism. Neurobiology of Disease, 167, 105669. https://doi.org/10.1016/j.nbd.2022.105669es
dc.identifier.issn0969-9961
dc.identifier.otherhttps://pubmed.ncbi.nlm.nih.gov/35219857/es
dc.identifier.urihttp://hdl.handle.net/20.500.12020/1541
dc.description.abstractDopaminergic denervation in patients with Parkinson's disease is associated with changes in brain metabolism. Cerebral in-vivo mapping of glucose metabolism has been studied in severe stable parkinsonian monkeys, but data on brain metabolic changes in early stages of dopaminergic depletion of this model is lacking. Here, we report cerebral metabolic changes associated with progressive nigrostriatal lesion in the pre-symptomatic and symptomatic stages of the progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkey model of Parkinson's Disease. Monkeys (Macaca fascicularis) received MPTP injections biweekly to induce progressive grades of dopamine depletion. Monkeys were sorted according to motor scale assessments in control, asymptomatic, recovered, mild, and severe parkinsonian groups. Dopaminergic depletion in the striatum and cerebral metabolic patterns across groups were studied in vivo by positron emission tomography (PET) using monoaminergic ([11C]-dihydrotetrabenazine; 11C-DTBZ) and metabolic (2-[18F]-fluoro-2-deoxy-d-glucose; 18F-FDG) radiotracers. 11C-DTBZ-PET analysis showed progressive decrease of binding potential values in the striatum of monkeys throughout MPTP administration and the development of parkinsonian signs. 18F-FDG analysis in asymptomatic and recovered animals showed significant hypometabolism in temporal and parietal areas of the cerebral cortex in association with moderate dopaminergic nigrostriatal depletion. Cortical hypometabolism extended to involve a larger area in mild parkinsonian monkeys, which also exhibited hypermetabolism in the globus pallidum pars interna and cerebellum. In severe parkinsonian monkeys, cortical hypometabolism extended further to lateral-frontal cortices and hypermetabolism also ensued in the thalamus and cerebellum. Unbiased histological quantification of neurons in Brodmann's area 7 in the parietal cortex did not reveal neuron loss in parkinsonian monkeys versus controls. Early dopaminergic nigrostriatal depletion is associated with cortical, mainly temporo-parietal hypometabolism unrelated to neuron loss. These findings, together with recent evidence from Parkinson's Disease patients, suggest that early cortical hypometabolism may be associated and driven by subcortical changes that need to be evaluated appropriately. Altogether, these findings could be relevant when potential disease modifying therapies become available.es
dc.language.isoenes
dc.publisherElsevieres
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleCerebral metabolic pattern associated with progressive parkinsonism in non-human primates reveals early cortical hypometabolismes
dc.typearticlees
dc.identifier.doihttps://doi.org/10.1016/j.nbd.2022.105669
dc.identifier.essn1095-953X
dc.journal.titleNeurobiology of diseasees
dc.page.initial105669es
dc.page.final105669es
dc.rights.accessRightsopenAccesses
dc.subject.areaCiencias Biomédicases
dc.subject.keywordParkinson Diseasees
dc.subject.keywordPositron Emission Tomography (PET)es
dc.subject.keyword[ 18F]-fluoro-2-deoxy-D-glucose ( 18F-FDG)es
dc.subject.keyword[ 11C]-dihydrotetrabenazine ( 11C-DTBZ)es
dc.subject.keywordGlucose Metabolismes
dc.subject.unesco32 Ciencias Médicases
dc.volume.number167es


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional